Using microglia and an unbiased screening method, investigators have identified almost 60 previously unknown targets for γ-secretase. Investigators from KU Leuven and colleagues published their results in Molecular Cell on Nov. 16, 2023. Read More
Dysfunction in the mitochondria contributes to the development of acute liver injury (ALI). There is emerging evidence indicating the mitochondria is key to maintain liver homeostasis and survival; thus, controlling its functioning is important for the treatment of liver diseases. Recent findings have identified transcription factor zinc-finger and homeoboxes 2 (ZHX2) to be a critical modulator of liver postnatal gene expression, cell proliferation and lipid homeostasis in the liver. Read More
Based on previous studies that have demonstrated the potential of growth hormone-releasing hormone receptor (GHRH-R) antagonists to modulate immune responses to bleomycin lung injury, researchers from the University of Miami and affiliated organizations aimed to evaluate the potential of the GHRH-R antagonist MIA-602 in a mouse model of rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury. Read More
Chiesi Farmaceutici SpA has disclosed imidazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
Scientists from the University of Cambridge, Harvard Medical School and collaborators investigated the potential of ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibition as a therapeutic strategy for restoring mitophagy to achieve neuroprotection in Parkinson’s disease. Read More
Research at the National Institute of Neurological Disorders and Stroke has led to the identification of a novel highly selective D2R antagonist. Read More
Treatment of osteoarthritis (OA) is still a challenge, since it is focused on symptom relief but fails at dealing with the progressive cartilage deterioration that occurs during the disease. Researchers from Innovo Therapeutics Inc. recently unveiled INV-1498, a caspase inhibitor, as a preclinical candidate for the treatment of OA. Read More
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders. Read More
Yale University has identified compounds reported to be useful for the treatment of dry age-related macular degeneration (AMD), Fuchs endothelial corneal dystrophy, cataract, glaucoma and keratoconus. Read More
Triple-negative breast cancer (TNBC) is a highly metastatic and heterogeneous type of tumor, representing 15% of breast cancer cases. To tackle the drug-resistant phenotype of TNBC, effective targeted combinatorial approaches are urgently needed. Writing in EMBO Molecular Medicine journal, researchers from the Centre for Genomic Regulation and collaborators demonstrate that the simultaneous inhibition of lysyl oxidase-like 2 (LOXL2) and bromodomain-containing protein 4 (BRD4) synergistically limits TNBC proliferation in vitro and in vivo. Read More
Revolution Medicines Inc. has divulged son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, neurofibromatosis type 1, cardiofaciocutaneous, Noonan, Costello and Legius syndrome (neurofibromatosis type 1-like syndrome), among others. Read More
Treeline Biosciences Inc. has described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1) targeting moiety via linker acting as Bcl-xL degradation inducers. Read More
Researchers from the National Research Centre of Egypt and Cairo University have reported the discovery of novel acetylcholinesterase (AChE) inhibitors as candidates for the management of Alzheimer’s disease. Read More
